The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1747
February 2, 2026
View Complete Issue         Table of Contents 2019 
Lumateperone (Caplyta) for Adjunctive Treatment of Depression
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Lumateperone (Caplyta) for Adjunctive Treatment of Depression
February 2, 2026 (Issue: 1747)
The FDA has approved the second-generation antipsychotic drug lumateperone (Caplyta — Intra-Cellular Therapies) for adjunctive treatment of major depressive disorder (MDD) in adults. Lumateperone was approved earlier for treatment of...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Lumateperone (Caplyta) for Adjunctive Treatment of Depression
Article code: 1747c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.